Jazz Pharmaceuticals (JAZZ) Other Non-Current Assets (2010 - 2026)

Jazz Pharmaceuticals' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• In Q1 2026, Other Non-Current Assets fell 21.1% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (down 21.1% YoY), while the FY2025 annual figure was $99.0 million, up 943.31% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $7.1 million, down from $99.0 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $99.0 million in Q4 2025, with the low at $4.4 million in Q3 2024.
• The 5-year median for Other Non-Current Assets is $8.6 million (2023), against an average of $20.0 million.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets slumped 88.25% in 2023, then surged 943.31% in 2025.
• Jazz Pharmaceuticals' Other Non-Current Assets stood at $55.1 million in 2022, then plunged by 88.25% to $6.5 million in 2023, then surged by 46.48% to $9.5 million in 2024, then soared by 943.31% to $99.0 million in 2025, then sank by 92.83% to $7.1 million in 2026.
• Business Quant data shows JAZZ's Other Non-Current Assets at $7.1 million in Q1 2026, $99.0 million in Q4 2025, and $8.0 million in Q3 2025.